Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAKINCOV: Anakinra and Ruxolitinib for Severe COVID-19
NCT04366232Phase 2Terminated
- Sponsor
- Centre Hospitalier Intercommunal de Toulon-La Seyne-sur-Mer
- Start
- Aug 2020
- Primary completion
- Oct 2020
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anakinra, ruxolitinib in coronavirus disease 2019 (COVID-19), sponsored by Centre Hospitalier Intercommunal de Toulon-La Seyne-sur-Mer. Started Aug 2020; status: terminated.
02
Drugs
anakinraruxolitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04366232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04366232.